Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Medium-term outcomes of canaloplasty for glaucoma

Search Title by author or title

Session Details

Session Title: Glaucoma

Session Date/Time: Monday 09/10/2017 | 08:00-10:30

Paper Time: 08:24

Venue: Room 4.1

First Author: : P.Santorum ITALY

Co Author(s): :    M. Simonazzi   E. Bertelli                 

Abstract Details

Purpose:

To evaluate the probability of a favourable outcome years after surgery in patients undergoing suture-based ab externo canaloplasty to treat elevated intraocular pressure (IOP) refractory to medications in eyes with primary open angle glaucoma (POAG) or pseudoexfoliation glaucoma (PEX).

Setting:

'San Maurizio' Regional Hospital, Bolzano, Italy. Secondary Referral, Non-Academic, National Health System Hospital.

Methods:

Retrospective case series. The charts of all patients that underwent canaloplasty for POAG or PEX between 2010 and 2016 were reviewed. Kaplan–Meier survival analysis, which takes varying length of follow-up into consideration, was performed to estimate the probability of a successful outcome 1, 2 ,3 and 4 years after surgery. Complete success was defined as not needing reoperation or drops to control the IOP, and qualified success as not needing reoperation to control the IOP.

Results:

Forty-nine eyes were included. Probability of complete success was 64%, 53%, 49% and 35% respectively 1, 2, 3, and 4 years after surgery. Probability of qualified success was 100%, 97%, 97% and 97% respectively 1, 2, 3, and 4 years after surgery. Canaloplasty was completed in 45 (92%) eyes with successful suture placement in 41 (84%) and viscodistension only in 4 (8%). Four (8%) eyes were converted to deep sclerectomy because of failure to cannulate Schlemm’s canal.

Conclusions:

Canaloplasty is both safe and effective in lowering IOP in POAG and PEX. A significant amount of patients remains drop-free even years after surgery. Reoperation for glaucoma is rare.

Financial Disclosure:

NONE

Back to previous